PEPTONIC MEDICAL (28L) - Cash Flow Conversion Efficiency
Based on the latest financial reports, PEPTONIC MEDICAL (28L) has a cash flow conversion efficiency ratio of -0.191x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-7.43 Million ≈ $-8.68 Million USD) by net assets (€38.83 Million ≈ $45.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of PEPTONIC MEDICAL to measure how much of total assets are equity-financed.
PEPTONIC MEDICAL - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how PEPTONIC MEDICAL's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore 28L operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
PEPTONIC MEDICAL Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PEPTONIC MEDICAL ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Aruma Resources Ltd
AU:AAJ
|
-0.373x |
|
TomaGold Corporation
F:OTM
|
1.375x |
|
APC Minerals Ltd
AU:APC
|
6.013x |
|
Accent Resources NL
AU:ACS
|
-0.036x |
|
VVC Exploration Corp.
V:VVC
|
-0.017x |
|
Fang Holdings Ltd
NYSE:SFUNY
|
-0.048x |
|
Melkior Resources Inc.
V:MKR
|
-0.045x |
|
Mountview Estates PLC
LSE:MTVW
|
0.060x |
Annual Cash Flow Conversion Efficiency for PEPTONIC MEDICAL (2021–2024)
The table below shows the annual cash flow conversion efficiency of PEPTONIC MEDICAL from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of PEPTONIC MEDICAL.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €48.55 Million ≈ $56.76 Million |
€-37.55 Million ≈ $-43.91 Million |
-0.774x | -72.34% |
| 2023-12-31 | €75.32 Million ≈ $88.06 Million |
€-33.81 Million ≈ $-39.53 Million |
-0.449x | +47.44% |
| 2022-12-31 | €47.09 Million ≈ $55.06 Million |
€-40.22 Million ≈ $-47.02 Million |
-0.854x | -12.45% |
| 2021-12-31 | €53.12 Million ≈ $62.10 Million |
€-40.34 Million ≈ $-47.16 Million |
-0.759x | -- |
About PEPTONIC MEDICAL
PEPTONIC medical AB (publ), a medical technology company, develops and sells intimate self-care products for women. The company offers products under the VagiVital brand, including a moisturizing gel for atrophy; an intimate calming gel for rapid relief of itching and irritation; moisturizing lubricant; a pH-balancing intimate wash/conditioner; self-test kits for diagnosing pre-menopause, menopau… Read more